Presidents Update March 2019
t’s looking as though the Epipen situation could get a whole lot better over the next few months. Mylan
has struggled to keep up with demand and only small supplies of generics have made it to the market.
Teva recently began shipping their generic but have only shipped limited quantities. They’ve announced
that they expect to capture 25% of the U.S. market by the end of this year. Sandoz recently started
shipping their generic version but again have so far shipped only a small amount.
The levothyroxine market is beginning to settle down. It is still difficult to keep it in stock but
we’re getting shipments from Sandoz every few days. Lupin, who recently received an approval, will
begin shipping theirs very soon.
Aceto Corp., a large chemical company, purchased Rising Pharmaceutical in 2010, Pack Pharma in 2014,
and in 2016 they paid over $400 million to acquire Citron Pharmaceutical. In 2015, Aceto’s stock broke
$30 per share. Just a few years later they’ve had to file Chapter 11 bankruptcy and will begin selling
off assets. They’re a big supplier on dozens of products so we’re working deligently to make sure that
we have back up sources in place.
We just received some great new short dates from Actavis/Teva, Sun, Strides, Amneal, and others. Make
sure that you check them out at AuburnGenerics.com or talk to your Auburn Account Manager for details.
And don’t forget to check out all of the great deals on GenericBid.com, our weekly auction site, where
you can get some of the best deals in the industry. If you haven’t tried Generic Bid, talk to your
Auburn Account Manager or just login using your AuburnGenerics.com username and password.